Expanding RNA Druggability with Small Molecules

The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field, such as successful determination and prediction of RNA structure and role in disease, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development.

With numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules, join leading biopharmaceutical directors, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes.

Expert Speakers at the 2020 RNA- Targeted Drug Discovery Summit Include:

Matthew Disney

Professor, Department of Chemistry & Neuroscience

The Scripps Research Institute & Scientific Founder of Expansion Therapeutics

Melissa Moore

Chief Scientific Officer

Moderna

Jen Petter

Founder and Chief Scientific Officer

Arrakis Therapeutics

Anna Marie

Pyle Sterling Professor

Yale University & HHMI Investigator

Nicholas Larsen

Director of Lead Discovery

H3 Biomedicine

Samie Jaffrey

Pharmacology Greenberg-Starr Professor

Weill Cornell Medicine

Adrian Krainer

Professor

Cold Spring Harbor Laboratory

Gene Yeo

Professor

University of California San Diego

2020 Partners Include:

Lucerna Official Logo

Other Events in the Undruggable Series: